Procyrion has administered treatment to its first patients using the Aortix percutaneous mechanical circulatory support (pMCS) device, as part of the A PRIORI (aortix therapy for perioperative reduction of renal injury) pilot trial.
The purpose of the study is to evaluate how well the Aortix device can protect against acute kidney injury (AKI) during cardiac surgery.
Four clinical locations in Australia—the Royal Adelaide Hospital, Monash Health, Princess Alexandra Hospital, and Macquarie University—will be used by Procyrion to enroll up to 50 patients in the study.
The Aortix pump is inserted into the descending thoracic aorta through a percutaneous catheter procedure at the start of the scheduled surgical operation.
According to the company, it aids in reducing the need for cardiac energy while directly improving perfusion to the kidneys.
The intra-aortic placement helps reduce the risk of device-related thrombotic stroke or harm to the heart or valves while the pump setup can be finished in under 15 minutes.
The design of the device allegedly makes use of fluid entrainment to give physiologically natural therapy while also improving renal artery flow and pressure.
According to Procyrion, the Aortix pump should be left in position for up to 48 hours after surgery to sustain increased renal perfusion.
In addition to lessening the strain on the recovering heart, this offers extra defense against postoperative risk factors for AKI.
